New hepatitis b drug aims for functional cure in phase 2 trial

NCT ID NCT06829329

First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 20 times

Summary

This study tests a new drug called AHB-137 in 105 adults with chronic hepatitis B who have not been treated before. The goal is to see if the drug can lower the hepatitis B virus to undetectable levels and possibly achieve a functional cure, meaning the virus stays under control even after stopping all medications. Participants will receive the drug and be monitored for safety and effectiveness over several months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Mengchao Hepatobiliary Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310052, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, 401336, China

  • The Third People's Hospital of Zhenjiang

    Zhenjiang, Jiangsu, China

Conditions

Explore the condition pages connected to this study.